Analysis of Antibacterial Drug Use and Resistance in Psychiatric Hospitals During the COVID-19 Epidemic

Study Background and Research Question

The COVID-19 pandemic introduced unprecedented challenges for healthcare systems globally, with psychiatric hospitals facing unique concerns due to the intersection of mental health, infection risk, and antimicrobial management. Psychiatric inpatients often have diminished self-care capacity and reduced immunity, elevating their vulnerability to bacterial infections. This context raises critical questions: How are antibacterial drugs utilized in psychiatric hospitals during a pandemic, and what are the resulting trends in bacterial resistance? The reference study conducted a hospital-wide retrospective analysis to provide evidence-based insight into these questions (reference paper).

Key Innovation from the Reference Study

This work is distinguished by its comprehensive use of both the hospital information system and the National Antibacterial Drug Clinical Application Monitoring Network to capture high-resolution data on antibiotic consumption, resistance rates, and microbiological practices throughout 2022. The integration of cumulative drug usage (defined daily doses, DDDs), resistance phenotypes, and comparative benchmarking against provincial and national data allows for a nuanced assessment of stewardship effectiveness and resistance emergence in a psychiatric hospital context. Crucially, the study quantifies not only raw usage but also the rate and quality of microbiological submissions—an important indicator of rational therapy (reference paper).

Methods and Experimental Design Insights

The investigators performed a retrospective analysis using antimicrobial usage and microbiological data from their institution’s information systems, cross-referenced with regional and national benchmarks. Antibiotic use metrics included:

• Antibiotic use rate (patients receiving antibiotics as a percentage of total admissions)
• Usage intensity (defined daily dose per 100 patient-days)
• Combined medication rate (proportion of patients receiving multiple antibiotics)
• Cumulative DDDs (total consumption standardized to WHO DDDs)
• Antibiotic cost as a proportion of total drug expenses
• Rate of microbiological submissions for antibacterial use
• Bacterial species identification and susceptibility profiles

This comprehensive, multi-dimensional approach enabled both quantitative and qualitative evaluation. Data analysis was performed in Excel, with detailed breakdowns of antimicrobial classes (e.g., cephalosporins, penicillins, quinolones) and pathogen resistance spectra (reference paper).

Core Findings and Why They Matter

The psychiatric hospital reported a notably low antibiotic use rate of 5.00% and an antibiotic use intensity of 3.07 (source: reference paper). These figures are significantly below both Jiangsu Province and national averages, indicating judicious antimicrobial stewardship. Additionally, antibiotic costs comprised just 3.95% of total drug expenditure. The rate of combined antibiotic therapy was also low (11.11%), reducing the risk of unnecessary broad-spectrum exposure.

However, the microbiological submission rate for antibacterial therapy was a remarkable 77.78%, much higher than regional and national levels. This underscores a strong commitment to evidence-based prescribing and diagnostic stewardship.

Despite these strengths, the data revealed persistent—and in some cases rising—bacterial resistance. Gram-negative pathogens demonstrated resistance primarily to penicillins, cephalosporins, and quinolones, with agents such as ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, and ciprofloxacin most affected. Gram-positive bacteria were particularly resistant to penicillins, macrolides, and quinolones, including penicillin, benzylpenicillin, erythromycin, levofloxacin, and ciprofloxacin. These findings highlight the complex relationship between even well-controlled antimicrobial use and the ongoing evolution of resistance, especially in vulnerable populations (reference paper).

The study therefore supports the need for continuous, real-time surveillance of both antimicrobial consumption and resistance patterns to inform targeted interventions, preserve treatment efficacy, and improve patient outcomes in psychiatric settings.

Comparison with Existing Internal Articles and Broader Context

While this reference study centers on antibacterial drug use and resistance in psychiatric hospitals, several internal articles provide complementary perspectives relevant to anti-inflammatory and immune modulation research. For example, the article "Gamma-linolenic Acid (GLA): Mechanistic Insights and Strategy" discusses the role of GLA as a weak Leukotriene B4 receptor antagonist and its potential in anti-inflammatory research, including apoptosis assays and disease modeling. This mechanistic framework is distinct from the direct antimicrobial stewardship focus of the reference paper but underscores the broader utility of immune-modulating agents in managing infection-related complications and inflammation in vulnerable populations.

Further, "Gamma-linolenic acid (GLA, SKU C5518): Data-Driven Solutions" addresses the reproducibility of GLA in cell viability and cytotoxicity workflows, which may be relevant for laboratories developing adjunctive assays to study the effects of inflammation or infection on cell health.

Although these internal resources primarily address anti-inflammatory and immune signaling research rather than direct antibiotic resistance, they provide valuable methodological insights and workflow solutions for studies at the intersection of infection, immunity, and pharmacological modulation.

Limitations and Transferability

The study’s strengths lie in its systematic data collection and benchmarking, but several limitations merit attention. The analysis was restricted to a single psychiatric institution and one year (2022), potentially limiting generalizability. Furthermore, the retrospective design and reliance on existing hospital data may introduce reporting or classification biases. The unique patient demographics and management protocols in psychiatric hospitals—such as closed management systems and high rates of patient interaction—may not be directly transferable to other healthcare settings.

Finally, while the study captures broad resistance trends, it does not dissect genetic or molecular mechanisms of resistance, nor does it address interventions to reverse resistance once established. Nevertheless, the work provides a valuable framework for ongoing surveillance and rational antimicrobial policy development in psychiatric and similar settings (reference paper).

Protocol Parameters

• Antibiotic use rate | 5.00% | psychiatric hospital during epidemic | Indicates judicious prescribing compared to regional/national averages | reference paper
• Usage intensity | 3.07 DDD/100 patient-days | same context | Allows benchmarking of antimicrobial exposure | reference paper
• Combined medication rate | 11.11% | same context | Reflects low rate of polypharmacy, minimizing resistance pressure | reference paper
• Microbiological submission rate | 77.78% | same context | Supports evidence-based therapy and stewardship | reference paper
• GLA for apoptosis assay | 0.087 mM (IC50) | HL60 promyelocytic cells | Enables cytotoxicity benchmarking in inflammation research | product_spec
• GLA for LTB4 inhibition | Ki ≈ 1 μM | neutrophil membrane binding | Mechanistic studies of LTB4 pathway antagonism | product_spec
• GLA dosing in vivo | 1 mg/kg | bronchoconstriction model | 53% inhibition of LTB4-induced bronchoconstriction | product_spec
• GLA working concentration | up to 100 mg/ml in DMSO/DMF | cell-based assays | Ensures solubility for in vitro workflows | product_spec

Research Support Resources

Researchers seeking to model inflammation, apoptosis, or immune signaling in laboratory settings may consider integrating Gamma-linolenic acid (GLA) (SKU C5518) into experimental workflows, leveraging its well-characterized properties as a weak LTB4 receptor antagonist and its utility in apoptosis and cytotoxicity assays (source: internal article; product_spec). For studies requiring robust and reproducible anti-inflammatory or cell viability protocols, the defined biochemical profile of GLA from APExBIO offers a practical resource, complementing the clinical surveillance and antimicrobial stewardship insights derived from the reference study.